Autolus Therapeutics plc

Contributing Author

Recent Articles by Autolus Therapeutics plc

May-14	Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates AUTL -7.02% GlobeNewswire
May-05	Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 AUTL GlobeNewswire
Apr-29	Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction AUTL GlobeNewswire
Apr-21	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL GlobeNewswire
Apr-07	Autolus Therapeutics to Participate in Upcoming Investor Conferences AUTL GlobeNewswire
Mar-27	Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates AUTL -6.20% GlobeNewswire
Mar-16	Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 AUTL GlobeNewswire
Feb-24	Autolus Therapeutics to Participate in Upcoming Investor Conferences AUTL +5.20% GlobeNewswire
Feb-04	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL GlobeNewswire
Jan-12	Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 AUTL -17.13% GlobeNewswire
Jan-06	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle Platform AUTL +7.53% GlobeNewswire
Dec-08	Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 AUTL -6.29% AUTL GlobeNewswire
Dec-08	Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 AUTL GlobeNewswire
Dec-01	Autolus Therapeutics Appoints Ryan Richardson to Board of Directors AUTL GlobeNewswire
Nov-25	NICE Recommends AUCATZYL (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ AUTL +12.10% GlobeNewswire
Nov-13	Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London AUTL +7.03% AUTL -5.88% GlobeNewswire
Nov-12	Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates AUTL -9.33% GlobeNewswire
Nov-03	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025 AUTL GlobeNewswire
Oct-30	Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 AUTL GlobeNewswire
Oct-27	Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 AUTL +7.84% GlobeNewswire
Oct-20	Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis AUTL GlobeNewswire
Oct-15	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL +6.17% GlobeNewswire
Sep-16	Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025 AUTL GlobeNewswire
Aug-12	Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates AUTL -12.75% GlobeNewswire
Jul-24	Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 AUTL GlobeNewswire
Jul-21	Autolus Therapeutics' CAR T Therapy AUCATZYL (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
Jul-15	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL -6.04% GlobeNewswire
Jun-12	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-29	Autolus Therapeutics to Participate in Upcoming Investor Conferences AUTL +6.06% GlobeNewswire
May-23	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
May-14	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-08	Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates AUTL +9.76% GlobeNewswire

Autolus Therapeutics plc

Recent Articles by Autolus Therapeutics plc

Upgrade your Finviz experience